Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Curacyte: Picking the best research

When Curacyte AG was founded in 2000, the company did not have a clear-cut technology or therapeutic focus. It had platforms in cancer and immunology and said it was developing therapies in cancer, immunodysregulation and thrombocytopenia, among others. Today, Curacyte has a lead in Phase III and another awaiting the start of clinical trials. In addition, the research pipeline has six compounds, four of them about to reach the preclinical stage.

CEO Helmut Giersiefen, a

Read the full 740 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers